格隆汇9月14日丨普蕊斯(301257.SZ)公布，持有公司股份5,474,040股(占公司总股本比例6.93%)的股东上 海观由投资发展有限公司－观由昭泰(嘉兴)创业投资合伙企业(有限合伙)(以下简称"观由昭泰")计划自公 告发布之日起15个交易日后的3个月内以集中竞价交易方式和/或大宗交易方式减持公司股份不超过 237.01万股(占公司总股本比例3.00%)。 （原标题：普蕊斯(301257.SZ)：股东观由昭泰拟减持不超3%公司股份） ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-057 普蕊斯（上海）医药科技开发股份有限公司 关于公司持股 5%以上股东减持股份预披露公告 公司股东上海观由投资发展有限公司－观由昭泰（嘉兴）创业投资合伙企 业（有限合伙）保证向本公司提供的信息内容真实、准确、完整、没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 持有普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）股份 5,474,040 股（占本公司总股本比例 6.93%）的股东上海观由投资发展有限公司－ 观由昭泰（嘉兴）创业投资合伙企业（有限合伙）（以下简称"观由昭泰"）计划 自本公告发布之日起 15 个交易日后的 3 个月内以集中竞价交易方式和/或大宗交 易方式减持本公司股份不超过 2,370,100 股（占本公司总股本比例 3.00%）。 公司于近日收到公司股东观由昭泰出具的《股份减持计划告知函》，现将具 体事项公告如下： （以下简称"《创投减持实施细则》"），并已申请成功且通过基金业协会备案。 根据《创投减持特别规定》《创投减 ...

Group 1 - The company, Puris (301257.SZ), announced that shareholder Guanyu Zhao Tai plans to reduce its holdings by up to 2,370,100 shares, which represents 3.00% of the company's total share capital [1]

Group 1: Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [1] - The company specializes in Site Management Organization (SMO) services to enhance the quality and efficiency of clinical trials in China [2] Group 2: Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 390.10 million and a net profit of CNY 54.16 million, with a net profit excluding non-recurring items of CNY 38.54 million [2] - The second quarter of 2025 saw a year-on-year revenue growth of 1.82% and a quarter-on-quarter growth of 21.06% [2] - The net profit for the second quarter increased by 45.17% year-on-year and 528.73% quarter-on-quarter [2] Group 3: Market Demand and Contracts - The company signed new contracts worth CNY 600 million in the first half of 2025, representing a year-on-year growth of 40.12% [2] - By the end of June 2025, the company had a backlog of contracts amounting to CNY 1.99 billion, a year-on-year increase of 9.45% [2] Group 4: Project Execution and Quality Control - The company has managed over 4,000 SMO projects, with 2,428 currently active [2] - Quality control is emphasized through the establishment of over 280 standard operating procedures and continuous training for employees [5] Group 5: Industry Trends and Opportunities - The Chinese innovative drug industry is entering a new phase of high-quality development, driven by policy support and active overseas business development (BD) transactions [2] - In the first half of 2025, the number of BD transactions in China's innovative drug sector reached 72, with a total transaction value of USD 60 billion [3]

Group 1 - On September 12, two listed companies had their restricted shares unlocked, with a total market value of approximately 5.33 million yuan [1] - The specific details of the restricted share unlock are as follows: - Company "好想你" (stock code: 002582) had 110,000 shares released from equity incentive restrictions [1] - Company "普蕊斯" (stock code: 301257) had 92,500 shares released from equity incentive restrictions [1]

Core Insights - On August 29, 2023, Prasis saw a stock price increase of 20.01% with a trading volume of 278 million yuan [1] - As of August 29, 2023, Prasis had a total margin trading balance of 62.69 million yuan, which is 1.82% of its market capitalization, indicating a low financing balance compared to the past year [1] - For the first half of 2025, Prasis reported a revenue of 390 million yuan, a year-on-year decrease of 1.08%, and a net profit attributable to shareholders of 54.16 million yuan, down 1.40% year-on-year [2] Financing and Margin Trading - On August 29, 2023, Prasis had a financing buy amount of 18.66 million yuan and a financing repayment of 20.31 million yuan, resulting in a net financing buy of -1.65 million yuan [1] - The margin trading data indicates that Prasis had no short selling activity on August 29, 2023, with a short selling balance of 0.00 yuan, which is at a high level compared to the past year [1] Shareholder and Institutional Holdings - As of July 31, 2023, Prasis had 8,735 shareholders, a decrease of 7.55% from the previous period, while the average number of circulating shares per shareholder increased by 8.16% to 8,622 shares [2] - As of June 30, 2025, among the top ten circulating shareholders, Tianhong Medical Health A held 1.43 million shares, a decrease of 17,600 shares from the previous period, while Rongtong Health Industry Flexible Allocation Mixed A/B increased its holdings by 100,000 shares to 1 million shares [3]

Group 1 - The company, Pruis, announced on the evening of September 9 that its third supervisory board's fifteenth meeting approved the proposal for revising and handling business change registration and filing [2]

Group 1 - The company announced the approval of multiple proposals during the 15th meeting of the third board of directors, including the re-election of non-independent directors [2]

Group 1 - The core point of the article is that the board of directors of the company has agreed to nominate Mr. Ma Yuping as a candidate for the non-independent director of the third board of directors [2]

普蕊斯（上海）医药科技开发股份有限公司 重大投资决策管理制度 普蕊斯（上海）医药科技开发股份有限公司 重大投资决策管理制度 第一章 总 则 第一条 为加强普蕊斯（上海）医药科技开发股份有限公司（以下简称"公 司"）重大投资决策管理水平，规范公司的重大投资行为，防范投资风险，保证 投资的安全，提高投资的效益，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《普蕊斯（上海）医药科技开发股份有限公司章程》（以下简称"《公司 章程》"）的有关规定，制定本制度。 第二条 本制度所称投资包括固定资产投资、金融资产投资和长期股权投资。 金融资产投资包括： （一）对子公司投资； （二）对合营公司投资； （三）对联营公司投资； （四）对被投资企业不具有共同控制或重大影响，并且在活跃市场中没有报 价、公允价值不能可靠计量的权益性投资。 第三条 本制度适用于公司及所属控股企业（以下简称所属企业）所有投资 业务。公司实行股东会、董事会、总经理分层决策制度，下属分公司无权决策对 外投资，子公司在公司授权范围内进行投资决策。 第四条 公司投资必须符合公司的发展战略，坚持成本效益原则，达到合理 投资收益标准，做到为公司全体股东谋求 ...